A varicella-zoster virus mutant impaired for latency in rodents, but not impaired for replication in cell culture

Virology

Volumn 399, Issue 2, 2010, Pages 194-200

  Ambagala, Aruna P N ^a   Krogmann, Tammy ^a   Qin, Jing ^b   Pesnicak, Lesley ^a   Cohen, Jeffrey I ^a  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

^b NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

Chickenpox; Latency; Shingles; Varicella zoster Virus

Indexed keywords

NEUTRALIZING ANTIBODY; VARICELLA ZOSTER VACCINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY TITER; ARTICLE; CARBOXY TERMINAL SEQUENCE; CONTROLLED STUDY; COTTON RAT; DRUG SAFETY; DRUG SCREENING; EMBRYO; FEMALE; GENE CASSETTE; GENE REARRANGEMENT; GUINEA PIG; HERPES ZOSTER; HUMAN; HUMAN CELL; IMMUNE RESPONSE; LATENT VIRUS INFECTION; MELANOMA CELL; NONHUMAN; NUCLEAR LOCALIZATION SIGNAL; OPEN READING FRAME; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; SITE DIRECTED MUTAGENESIS; VARICELLA ZOSTER VIRUS; VIROGENESIS; VIRUS GENOME; VIRUS LATENCY; VIRUS MUTANT; VIRUS REACTIVATION; VIRUS REPLICATION; VIRUS STRAIN;

ANIMALS; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; CELL LINE, TUMOR; DNA, VIRAL; FEMALE; GUINEA PIGS; HERPES ZOSTER; HERPESVIRUS 3, HUMAN; HUMANS; IMMEDIATE-EARLY PROTEINS; SEQUENCE DELETION; SIGMODONTINAE; VIRAL ENVELOPE PROTEINS; VIRUS LATENCY;

CAVIA; HUMAN HERPESVIRUS 3; RODENTIA; SIGMODON;

EID: 77249141985     PISSN: 00426822     EISSN: 10960341     Source Type: Journal    
DOI: 10.1016/j.virol.2010.01.007     Document Type: Article

References (37)

1. Baiker A., Bagowski C., Ito H., Sommer M., Zerboni L., Fabel K., Hay J., Ruyechan W., and Arvin A.M. The immediate-early 63 protein of varicella-zoster virus: analysis of functional domains required for replication in vitro and for T-cell and skin tropism in the SCIDhu model in vivo. J. Virol. 78 (2004) 1181-1194
2. Baudoux L., Defechereux P., Schoonbroodt S., Merville M.P., Rentier B., and Piette J. Mutational analysis of varicella-zoster virus major immediate-early protein IE62. Nucleic Acids Res. 23 (1995) 1341-1349
3. Broyer M., Tete M.T., Guest G., Gagnadoux M.F., and Rouzioux C. Varicella and zoster in children after kidney transplantation: long term results of vaccination. Pediatrics 99 (1997) 35-39
4. Brunell P.A., Taylor-Wiedeman J., Geiser C.F., Frierson L., and Lydick E. Risk of herpes zoster in children with leukemia: varicella vaccine compared with history of chickenpox. Pediatrics 77 (1986) 53-56
5. Centers for Disease Control. Recommended immunization schedules for persons aged 0-18 years - United States. Morb. Mortal. Wkly. Rep. 55 51 (2007) Q1-Q4
6. Cohen J.I., Cox E., Pesnicak L., Srinivas S., and Krogmann T. The varicella-zoster virus open reading frame 63 latency-associated protein is critical for establishment of latency. J. Virol. 78 (2004) 11833-11840
7. Cohen J.I., Krogmann T., Bontems S., Sadzot C., and P esnicak L. Regions of the varicella-zoster virus ORF63 latency-associated protein important for efficient replication in vitro are also critical for efficient establishment of latency. J. Virol. 79 (2005) 5069-5077
8. Cohen J.I., Krogmann T., Ross J.P., Pesnicak L., and Prikhodko E. Varicella-zoster virus ORF4 latency-associated protein is important for establishment of latency. J. Virol. 79 (2005) 6969-6975
9. Cohen J.I., Krogmann T., Pesnicak L., and Ali M.A. Absence or overexpression of the varicella-zoster virus (VZV) ORF29 latency-associated protein impairs late gene expression and reduces latency in a rodent model. J. Virol. 81 (2007) 1586-1591
10. Cohrs R.J., Randall J., Smith J., Gilden D.H., Dabrowski C., van Der Keyl H., and Tal-Singer R. Analysis of individual human trigeminal ganglia for latent herpes simplex virus type 1 and varicella-zoster virus nucleic acids using real-time PCR. J. Virol. 74 (2000) 11464-11471
11. Cohrs R.J., Gilden D.H., Kinchington P.R., Grinfeld E., and Kennedy P.G. Varicella-zoster virus gene 66 transcription and translation in latently infected human ganglia. J. Virol. 77 (2003) 6660-6665
12. Cohrs R.J., Gilden D.H., Gomi Y., Yamanishi K., and Cohen J.I. Comparison of virus transcription during lytic infection of the Oka parental and vaccine strains of Varicella-Zoster virus. J. Virol 80 (2006) 2076-2082
13. Cohrs R.J., and Gilden D.H. Prevalence and abundance of latently transcribed VZV genes in human ganglia. J. Virol. 81 (2007) 2950-2956
14. Grinfeld E., Sadzot-Delvaux C., and Kennedy P.G. Varicella-zoster virus proteins encoded by open reading frames 14 and 67 are both dispensable for the establishment of latency in a rat model. Virology 323 (2004) 85-90
15. Grinfeld E., Ross A., Forster T., Ghazal P., and Kennedy P.G. Genome-wide reduction in transcriptomal profiles of varicella-zoster virus vaccine strains compared with parental Oka strain using long oligonucleotide microarrays. Virus Genes 38 (2009) 19-29
16. Hammerschlag M.R., Gershon A., Steinberg S., Clarke L., and Gelb L. Herpes zoster in an adult recipient of live attenuated varicella vaccine. J. Infect. Dis. 160 (1989) 535-537
17. Hardy I., Gershon A.A., Steinberg S.P., LaRussa P., and the Varicella Vaccine Collaborative Study Group. The incidence of zoster after immunization with live attenuated varicella vaccine. N. Engl. J. Med. 325 (1991) 1545-1550
18. Kamiya H., Kato T., Isaji M., et al. Immunization of acute leukemic children with a live varicella vaccine (Oka strain). Biken. J. 27 (1984) 99-102
19. Kennedy P.G., Grinfeld E., and Bell J.E. Varicella-zoster virus gene expression in latently infected and explanted human ganglia. J. Virol. 74 (2000) 11893-11898
20. Kinchington P.R., Fite K., and Turse S.E. Nuclear accumulation of IE62, the varicella-zoster virus (VZV) major transcriptional regulatory protein, is inhibited by phosphorylation mediated by the VZV open reading frame 66 protein kinase. J. Virol. 74 (2000) 2265-2277
21. Krause P.R., and Klinman D.M. Varicella vaccination: evidence for frequent reactivation of the vaccine strain in healthy children. Nat. Med. (2000) 451-454
22. LaRussa P., Steinberg S.P., Shapiro E., Vazquez M., and Gershon A.A. Varicella vaccine revisted [letter]. Nat. Med. 12 (2000) 1299
23. Liang M.G., Heidelberg K.A., Jacobson R.M., and McEvoy M.T. Herpes zoster after varicella vaccination. J. Am. Acad. Dermatol. 38 (1998) 761-763
24. Lynch J.M., Kenyon T.K., Grose C., Hay J., and Ruychen W.T. Physical and functional interaction between the varicella-zoster virus IE63 and IE62 proteins. Virology 302 (2002) 71-82
25. Meier J.L., Holman R.P., Croen K.D., Smialek J.E., and Straus S.E. Varicella-zoster virus transcription in human trigeminal ganglia. Virology 193 (1993) 193-200
26. Oxman M.N., Levin M.J., Johnson G.R., Schmader K.E., Straus S.E., Gelb L.D., et al. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. N. Engl. J. Med. 352 (2005) 2271-2284
27. Plotkin S.A., Starr S.E., Connor K., et al. Zoster in normal children after varicella vaccine. J. Infect. Dis. 159 (1989) 1000-1001
28. Quinlivan M.L., Gershon A.A., Al Bassam M.M., et al. Natural selection for rash-forming genotypes of the varicella-zoster vaccine virus detected within immunized human hosts. Proc. Natl. Acad. Sci. U. S. A. 104 (2007) 208-212
29. Sato H., Pesnicak L., and Cohen J.I. Varicella-zoster virus open reading frame 2 encodes a membrane phosphoprotein that is dispensable for viral replication and for establishment of latency. J. Virol. 76 (2002) 3575-3578
30. Sato H., Callanan L.D., Pesnicak L., Krogmann T., and Cohen J.I. Varicella-zoster virus (VZV) ORF17 protein induces RNA cleavage and is critical for replication of VZV at 37 °C, but not 33 °C. J. Virol. 76 (2002) 11012-11023
31. Sato H., Pesnicak L., and Cohen J.I. Varicella-zoster virus ORF47 protein kinase which is required for replication in human T cells, and ORF66 protein kinase which is expressed during latency, are dispensable for establishment of latency. J. Virol. 77 (2003) 11180-11185
32. Sato H., Pesnicak L., and Cohen J.I. Use of a rodent model to show that varicella-zoster virus ORF61 is dispensable for establishment of latency. J. Med. Virol. 70 Suppl 1 (2003) S79-S81
33. Seward J., Jumann A., and Schmid S. Varicella vaccine revisted [letter]. Nature Med. 12 (2000) 1298-1299
34. Sharrar R.G., LaRussa P., Galea S.A., Steinberg S.P., Sweet A.R., Keatley M., et al. The postmarketing safety profile of varicella vaccine. Vaccine 19 (2001) 916-923
35. Spengler M.L., Ruyechan W.T., and Hay J. Physical interaction between two varicella zoster virus gene regulatory proteins, IE4 and IE62. Virology 272 (2000) 375-381
36. Takahashi M., Otsuka T., Okunu Y., Asano Y., Yazaki T., and Isomura S. Live vaccine used to prevent the spread of varicella in children in hospital. Lancet 2 (1974) 1288-1290
37. Wise R.P., Salive M.E., Braun M.M., Mootrey G.T., Seward J.F., Rider L.G., et al. Postlicensure safety surveillance for varicella vaccine. JAMA 284 (2000) 1271-1279